Mir Ali, MD
Pulmonary Disease · Clayton, NCNPI 1083800965
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,023 of the $147,248 with a category attached, or 82.9%. 30 manufacturers reported payments, led by GSK at 47.9% of the total. Reporting peaked in 2021 at $38,853 and has fallen 97.8% since, to $849 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 436 payments — averaging $337.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$71K
- Mylan Specialty L.p.$48K
- AstraZeneca$18K
- Sunovion Pharmaceuticals Inc.$7K
- Viiv Healthcare Company$2K
- Boehringer Ingelheim$258
- plus $2K from 24 others
What the payments were for
- Consulting fees$7,9925%
- Speaking & faculty fees$122,02383%
- Travel & lodging$11,2648%
- Food & beverage$5,8854%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $70,554 |
| Mylan Specialty L.p. | 120 | $48,279 |
| AstraZeneca | 64 | $17,777 |
| Sunovion Pharmaceuticals Inc. | 26 | $7,038 |
| Viiv Healthcare Company | 1 | $1,600 |
| Boehringer Ingelheim | 13 | $258 |
| Actelion Pharmaceuticals US, Inc. | 13 | $247 |
| United Therapeutics Corporation | 30 | $226 |
| Jazz Pharmaceuticals Inc. | 8 | $207 |
| Harmony Biosciences LLC | 4 | $142 |
| Genentech USA, Inc. | 8 | $136 |
| Regeneron Healthcare Solutions, Inc. | 4 | $82 |
| Verona Pharma, Inc. | 3 | $69 |
| Advanced Respiratory, Inc | 2 | $68 |
| Baxter Healthcare | 3 | $67 |
| Paratek Pharmaceuticals, Inc. | 3 | $59 |
| Insmed, Inc. | 2 | $56 |
| Philips North America LLC | 3 | $53 |
| Electromed, Inc. | 4 | $48 |
| Grifols USA, LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Novo Nordisk | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| Viatris Specialty LLC | 1 | $22 |
| Merck | 1 | $21 |
| Novartis | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$57,850
- Yupelri$47,217
- BREZTRI$16,678
- LONHALA MAGNAIR$6,570
How this compares
$147,248 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 725 | $533,056 |
| OpsumitMacitentan | 20 | $254,916 |
| Ambrisentan | 27 | $76,950 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $42,921 |
| Roflumilast | 723 | $36,289 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $23,912 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $9,836 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,397 |
| Fluticasone Propionate | 168 | $4,459 |
| Montelukast Sodium | 657 | $4,096 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,826 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,915 |
| Ventolin HfaAlbuterol Sulfate | 18 | $987 |
| Amitriptyline Hcl | 38 | $721 |
| Prednisone | 92 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $70,554 | $541,453743 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $247 | $254,91620 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $17,777 | $46,74781 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $258 | $33,74867 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Clayton
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.